Dedicated to the pursuit of justice

OxyElite Pro Linked to Liver Problems, Death

OxyElite Pro, a popular dietary supplement used for both weight loss and muscle building, is under increasing scrutiny following an outbreak of liver disease in which two patients required liver transplants, and a third died. Marines Warned of Liver Damage

Health officials in Hawaii are asking stores to stop selling the product, with the Marine Corps warning troops that it may have been a factor in an outbreak of liver disease. Marines Warned Against OxyElite Pro

In fact, the supplement is a common link in 24 cases of acute hepatitis and liver failure in Hawaii. Supplement Illegal to Sell in Hawaii


In response, the Hawaii State Dept. of Health is alerting local retailers and requesting the voluntary removal from sale of the product – pending an ongoing investigation – and advising the public to discontinue use of the product at this time.

Additionally, “the FDA has sent a warning letter to the manaufacturer, Dallas-based USPlab, noting that its OxyElite Pro supplement now contains an ingredient called aegeline that has no history in the food supply and has not been properly tested for safety. OxyElite Pro Pulled From Shelves

USPlabs LLC, has said it will stop distributing OxyElite Pro, but maintained in a statement that it “stands by the safety of all of its products” and that “the cluster of liver issues in Hawaii is a complete mystery.” Supplements Linked to Liver Failure, Hepatitis

The supplement first came under fire two years ago.  At the time OxyElite Pro and other fitness supplements that contained a stimulant called DMAA were pulled from military shelves – following the collapse and death of three soldiers during training at Fort Bliss, Texas.

Service members and their families who believe they have been harmed by the use of this product should contact their health care provider.

Additionally, health care providers are asked to report any adverse events related to the use of OxyElite Pro to the FDA MedWatch Safety Information and Adverse Reporting Program at Med-Watch